Palmer A M, Steele J E, Lowe S L, Bowen D M
Department of Neurochemistry, Institute of Neurology, London, U.K.
Clin Neuropharmacol. 1990 Feb;13(1):58-66. doi: 10.1097/00002826-199002000-00006.
Alzheimer's disease may be associated with an early and clinically relevant degeneration of some cortical excitatory amino acid-releasing neurons. Tetrahydro-9-aminoacridine (tacrine) might be an effective drug for the treatment of the disease. Various pharmacological paradigms (in rats) related to amino acid release are shown here to be modified both in vivo and in vitro by the drug. These effects are only observed with high concentrations, so it is unlikely that tacrine acts through amino acid release in humans.
阿尔茨海默病可能与某些皮质兴奋性氨基酸释放神经元的早期且具有临床相关性的退化有关。四氢氨基吖啶(他克林)可能是治疗该疾病的一种有效药物。此处显示,与氨基酸释放相关的各种药理学范式(在大鼠中)在体内和体外均会被该药物改变。这些效应仅在高浓度时才会观察到,因此他克林在人体内不太可能通过氨基酸释放发挥作用。